YAQRIT LIMITED

Their core work

YAQRIT is a UK-based SME focused on developing therapeutic devices and treatments for severe liver disease, particularly acute-on-chronic liver failure. They specialize in liver dialysis technology, extracorporeal liver assist devices, and advanced carbon-based materials for treating liver cirrhosis and related conditions. Their work spans from nanoporous carbon therapeutics to pharmacological interventions combining growth factors with immune modulation, positioning them as a translational medicine company bridging material science and hepatology.

What they specialise in

How they've shifted over time

YAQRIT's early work (2015-2017) centered on material science applied to liver disease — specifically nanoporous carbon as a therapeutic platform for cirrhosis and fatty liver disease (CARBALIVE). By 2017-2021, they moved into medical device development with the DIALIVE liver dialysis system (ALIVER). Their most recent project (A-TANGO, 2021-2026) represents a further shift toward pharmacological and immunological approaches, combining growth factor therapy with toll-like receptor antagonism — moving from devices to drug-based interventions.

YAQRIT is evolving from materials and devices toward pharmacological interventions for liver failure, suggesting growing capability in drug development and immune modulation — a direction likely to expand into clinical trial partnerships.

How they like to work

YAQRIT consistently participates as a partner rather than leading consortia, which is typical for a specialized SME contributing deep domain expertise to larger research efforts. With 32 unique partners across 10 countries in just 3 projects, they operate within large, diverse consortia — indicating they are comfortable in complex multi-partner environments. Their consistent role as participant suggests they bring specific technical capabilities (devices, materials, clinical know-how) rather than managing overall project direction.

YAQRIT has built a broad European network of 32 partners across 10 countries through just 3 projects, reflecting involvement in large health research consortia. Their collaborative reach is notably wide for an SME of this size.

What sets them apart

YAQRIT occupies a rare niche at the intersection of material science, medical devices, and pharmacology — all applied specifically to liver failure. Unlike academic hepatology groups, they bring commercial product development focus to liver dialysis and therapeutic interventions. For consortium builders, they offer a specialized SME partner with proven H2020 experience and deep expertise in a disease area (liver failure) that has very few dedicated commercial players in Europe.

Highlights from their portfolio

• ALIVER
  Largest funding (EUR 2.8M) and developed DIALIVE, a tangible liver dialysis device — their most product-oriented project.
• A-TANGO
  Most recent and longest-running project (2021-2026), signaling a strategic pivot toward drug-based immunomodulation for liver failure.
• CARBALIVE
  Their earliest H2020 project, establishing their foundation in nanoporous carbon materials applied to liver disease.